$2.61
1.89% yesterday
Nasdaq, Sep 27, 09:50 pm CET
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

AbCellera Biologics Inc Stock price

$2.61
+0.00 0.00% 1M
-1.88 41.87% 6M
-3.10 54.29% YTD
-2.10 44.59% 1Y
-18.38 87.57% 3Y
-17.39 86.95% 5Y
-17.39 86.95% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.05 1.95%
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

Key metrics

Market capitalization $754.35m
Enterprise Value $131.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.96
P/S ratio (TTM) P/S ratio 22.82
P/B ratio (TTM) P/B ratio 0.68
Revenue growth (TTM) Revenue growth -77.23%
Revenue (TTM) Revenue $33.06m
EBIT (operating result TTM) EBIT $-269.29m
Free Cash Flow (TTM) Free Cash Flow $-168.25m
Cash position $695.36m
EPS (TTM) EPS $-0.53
P/E forward negative
P/S forward 22.53
EV/Sales forward 3.91
Short interest 7.74%
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AbCellera Biologics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
89%
Hold
11%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
33 33
77% 77%
100%
- Direct Costs 61 61
-
185%
-28 -28
-
-86%
- Selling and Administrative Expenses 13 13
54% 54%
39%
- Research and Development Expense 167 167
16% 16%
504%
-208 -208
229% 229%
-629%
- Depreciation and Amortization 61 61
68% 68%
185%
EBIT (Operating Income) EBIT -269 -269
170% 170%
-815%
Net Profit -153 -153
107% 107%
-464%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Neutral
Business Wire
one day ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.
Neutral
Business Wire
29 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in September.
Negative
Seeking Alpha
about one month ago
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 586
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today